Studies in esophageal adenocarcinoma and head and neck squamous cell carcinoma patients treated with neoCRT or neoadjuvant chemoimmunotherapy have revealed cellular and molecular features, such as CD103+CD8+ T cells, associated with treatment response.[19, 20] In parallel, tertiary lymphoid structures (TLSs)—organized aggregates rich in T and B cells—have also been associated with improved responses to neoadjuvant immunotherapy across various cancer types.[21, 22] Within this immune‐rich context, tumor‐reactive T cells play a central role in mediating cytotoxic effects. This evidence concerns the gene CD8A and neoplasm.